Oct 3 |
This IPO Biotech Stock Could Be the Next Eli Lilly
|
Oct 1 |
BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement
|
Sep 30 |
BioAge Labs: Weighing The Risks And Rewards Of A Biotech Revival
|
Sep 27 |
Biotech IPOs return as sector recovers after funding overhang
|
Sep 26 |
BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rises On Upsized IPO
|
Sep 26 |
A weight loss drug developer's stock soars after a $198 million IPO
|
Sep 26 |
BioAge stock rallies 29% following upsized $198M IPO
|
Sep 26 |
BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq
|
Sep 26 |
Weight-loss drug developer BioAge Labs aims to raise $198M from U.S. IPO
|
Sep 26 |
BioAge Labs Announces Pricing of Upsized Initial Public Offering
|